Xenical · 4.1 Therapeutic indications · 1

HOS-083518 · has-adverse-reaction-information · PDF-Seite 5

Adverse reactions to orlistat are largely gastrointestinal in nature. The incidence of adverse events decreased with prolonged use of orlistat. Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000) including isolated reports. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following table of undesirable effects (first year of treatment) is based on adverse events that occurred at a frequency of > 2 % and with an incidence ≥ 1 % above placebo in clinical trials of 1 and 2 years duration: 5  System organ class Adverse reaction/event Nervous system disorders Very common: Headache Respiratory, thoracic and mediastinal disorders Very common: Upper respiratory infection Common: Lower respiratory infection Gastrointestinal disorders Very common: Abdominal pain/discomfort Oily spotting from the rectum Flatus with discharge Faecal urgency Fatty/oily stool Flatulence Liquid stools Oily evacuation Increased defecation Common: Rectal pain/discomfort Soft stools Faecal incontinence Abdominal distension* Tooth disorder Gingival disorder Renal and urinary disorders Common: Urinary tract infection Metabolism and nutrition disorders Very common: Hypoglycemia* Infections and infestations Very common: Influenza General disorders and administration site conditions

Auszug; vollständigen Abschnitt im Original lesen.

HOS-083514 · has-contraindication-information · PDF-Seite 2

- Hypersensitivity to the active substance or to any of the excipients. - Chronic malabsorption syndrome. - Cholestasis. - Breast-feeding. 2

HOS-083513 · has-indication-information · PDF-Seite 2

Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI > 28 kg/m²) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5 % of the body weight as measured at the start of therapy.

HOS-083516 · has-interaction-information · PDF-Seite 3

Ciclosporin A decrease in ciclosporin plasma levels has been observed in a drug-drug-interaction study and also reported in several cases, when orlistat was administered concomitantly. This can lead to a decrease of immunosuppressive efficacy. Therefore the combination is not recommended (see section 4.4). However, if such concomitant use is unavoidable, more frequent monitoring of ciclosporin blood levels should be performed both after addition of orlistat and upon discontinuation of orlistat in ciclosporin treated patients. Ciclosporin blood levels should be monitored until stabilised. Acarbose In the absence of pharmacokinetic interaction studies, the concomitant administration of orlistat with acarbose should be avoided. Oral anticoagulants 3 When warfarin or other anticoagulants are given in combination with orlistat, international normalised ratio (INR) values should be monitored (see section 4.4). Fat soluble vitamins Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K). The vast majority of patients receiving up to four full years of treatment with orlistat in clinical studies had vitamin A, D, E and K and beta-carotene levels that stayed within normal range. In order to ensure adequate nutrition, patients on a weight control diet should be advised to have a diet rich in fruit and vegetables and use of a multivitamin supplement could be considered. If a multivitamin supplement is recommended, it should be taken at least two hours after the administration of orlistat or at bedtime. Amiodarone A slight decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly. In patients receiving amiodarone treatment, the clinical relevance of this effect remains unknown but may become clinically relevant in some cases. In patients receiving concomitant amiodarone treatment, reinforcement of clinical and ECG monitoring is warranted. Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded. Therefore, these patients should be monitored for possible changes in the frequency and/or severity of convulsions. Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The mechanism, althoug

Auszug; vollständigen Abschnitt im Original lesen.

HOS-083517 · has-pregnancy-information · PDF-Seite 4

For orlistat no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Caution should be exercised when prescribing to pregnant women. As it is not known whether orlistat is secreted into human milk, orlistat is contra-indicated during breast-feeding.

HOS-083515 · has-warning-information · PDF-Seite 3

In clinical trials, the decrease in bodyweight with orlistat treatment was less in type II diabetic patients than in non-diabetic patients. Antidiabetic medicinal product treatment may have to be closely monitored when taking orlistat. Co-administration of orlistat with ciclosporin is not recommended (see section 4.5). Patients should be advised to adhere to the dietary recommendations they are given (see section 4.2). The possibility of experiencing gastrointestinal adverse reactions (see section 4.8) may increase when orlistat is taken with a diet high in fat (e.g. in a 2000 kcal/day diet, > 30 % of calories from fat equates to > 67 g of fat). The daily intake of fat should be distributed over three main meals. If orlistat is taken with a meal very high in fat, the possibility of gastrointestinal adverse reactions may increase. Cases of rectal bleeding have been reported with Xenical. Prescribers should investigate further in case of severe and/or persistent symptoms. The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea (see section 4.5). Coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants (see section 4.5 and 4.8). The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes to renal failure. This risk is increased in patients with underlying chronic kidney disease and/or volume depletion (see section 4.8). Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The mechanism, although not proven, may involve a decreased absorption of iodine salts and/or levothyroxine (see section 4.5). Antiepileptics patient: Orlistat may unbalance anticonvulsant treatment by decreasing the absorption of antiepileptic drugs, leading to convulsions (see section 4.5). Antiretrovirals for HIV: Orlistat may potentially reduce the absorption of antiretroviral medicines for HIV and could negatively affect the efficacy of antiretroviral medications for HIV (see section 4.5). This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free’.